Tumours harbouring RET mutations or fusions respond to the targeted RET inhibitor selpercatinib, with object response rates of 56% and 62% respectively, post first-line therapy.

This analysis of data from cohorts of patients with RET-altered thyroid cancer participating in the ongoing LIBRETTO-001 study demonstrated marked anti-tumour activity following treatment with selpercatinib (LOXO-292), which was well-tolerated. Based on these findings, the investigators are planning to submit a new drug application with the FDA in late 2019.

ESMO 2019 abstract LBA93